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Abstract: Thymosin beta 4 (Tβ4) is a low molecular weight protein present in all cells except 
erythrocytes. Although Tβ4 is the major monomeric actin-sequestering peptide in cells and can 
depolymerize F-actin, evidence is mounting to support the idea that it has multiple, seemingly 
diverse, cellular functions. In cornea, as in other tissues, Tβ4 promotes cell migration and wound 
healing, has anti-inﬂ  ammatory properties, and suppresses apoptosis. In this review we discuss 
the current state of knowledge regarding the effects of Tβ4 in maintaining the healthy, functional 
cornea. The clinical implications of the use of Tβ4 as a wound healing and anti-inﬂ  ammatory 
agent are discussed.
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Corneal epithelial wounds: overview
The cornea consists of three types of cells, epithelial, stromal, and endothelial. It is 
avascular, transparent, and the most sensitive tissue in the body. The cornea functions as 
an optical lens that refracts light, but it also contributes to the rigid shell of the eyeball. 
In order to optimally refract light and ensure clear vision, the cornea must maintain 
optical transparency. This is accomplished in the stroma by a well-organized arrange-
ment of collagen ﬁ  bers into lamellae (Meek et al 2003). The endothelium functions 
to preserve corneal transparency by regulating the level of hydration in the stroma. 
The corneal epithelium also contributes to the maintenance of corneal transparency 
(Verkman 2003). Damage to the corneal epithelium caused by chemical, physical or 
microbial insults can lead to swelling of the stroma, the activation of stromal ﬁ  broblasts, 
and the inﬁ  ltration of inﬂ  ammatory cells, leading to the loss of corneal transparency 
and integrity. Timely resurfacing of the epithelium after injury is thus essential in 
preventing the loss of normal corneal function and loss of vision.
Following wounding, corneal epithelial healing occurs in several stages by a com-
bination of three separate mechanisms, migration, mitosis, and differentiation (Gipson 
and Inatomi 1995). Through a highly organized chain of events, cells must migrate to 
cover the denuded stroma, and then proliferate and differentiate to restore the normal 
multi-layered epithelial cytoarchitecture (Zhao et al 2003). In most instances, corneal 
epithelial defects caused by a simple injury, such as a surface scrape or abrasion, are 
healed promptly. However, in individuals with certain clinical disorders, such as 
diabetic keratopathy, basement membrane dystrophies, neuropathies, and infections, 
corneal epithelial defects persist and do not respond to conventional treatment regimens 
(Sanchez-Thorin 1998). Not only is the rate of corneal re-epithelialization important 
after injury, the re-normalization of the epithelial cytoarchitecture and re-establishment 
of the epithelial barrier are paramount (Huang et al 1990).
In order to re-establish the epithelial barrier, cells migrate over the denuded surface 
of the cornea in a manner that is dependent both on the interaction of the cells with the 
underlying substrate via cell-extracellular matrix adhesions called hemidesmosomes, Clinical Ophthalmology 2007:1(3) 202
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and on cell–cell adhesions called desmosomes (Suzuki 
et al 2003). Regeneration of cell adhesions to reconstitute 
the epithelial barrier protects the cornea from infectious 
agents and also is important to prevent the persistence of 
corneal epithelial fragility that can lead to recurrent erosions 
(McCartney and Cantu-Crouch 1992).
The wound repair process is intricately linked to a 
complex inﬂ  ammatory response that must be precisely regu-
lated to ensure proper healing and optimal visual outcome. 
Inﬁ  ltration of inﬂ  ammatory cells into injured corneal tissue 
is a hallmark of wound repair (Kenyon 1985). Retardation 
of epithelial recovery by persistent inﬂ  ammation, release 
of enzymatic products from resident corneal cells and 
inﬁ  ltrating inﬂ  ammatory cells, and stimulation by cytokines 
and chemokines, all contribute to poor re-epithelialization. 
With regard to the cornea, detailed information on cytokine 
expression and activity is emerging, and great interest cen-
ters around identifying which cytokines and chemokines 
are induced in the cornea by a particular stimulant or insult 
(Wakeﬁ  eld and Lloyd 1992; Cubitt et al 1993, 1995).
Although much progress has been made in understand-
ing how the cornea heals, current pharmacological therapies 
that accelerate and/or promote epithelial healing are severely 
limited. Clinicians still mainly aim to provide the patient with 
an environment conducive to healing and rely on the eye’s 
innate ability to repair itself. Emerging evidence from our 
laboratory and others shows that thymosin beta 4 (Tβ4) is a 
novel wound healing agent that promotes corneal repair and 
decreases inﬂ  ammation after injury. In this review, we focus 
on the studies that provide evidence for the potential clinical 
usage of Tβ4 as a corneal wound healing agent.
Properties of Tβ4
Tβ4 is a 43-amino acid, 4.9 kDa protein originally isolated 
from bovine thymus (Low et al 1981; Goodall et al 1983; Yu 
et al 1994). Tβ4 is the major monomeric actin-sequestering 
peptide in cells and can depolymerize F-actin. For example, 
it has been found to depolymerize cystic ﬁ  brosis-derived 
sputum actin in both a dose-dependent and a time-dependent 
manner (Rubin et al 2006). Tβ4 inﬂ  uences T cell differen-
tiation (Hu et al 1981; Low and Goldstein 1984). It has no 
signal sequence (Gondo et al 1987) but is found in serum 
(Naylor et al 1984; Weller et al 1988). Tβ4 does not appear 
to bind to either heparin or other extracellular matrix mol-
ecules, suggesting it can rapidly diffuse throughout tissue 
compartments.
Tβ4 is an ubiquitous polypeptide, highly conserved across 
species, and is found at concentrations of 1 × 10−5 to 5.6 × 
10−1 M in a variety of tissues and cell types, yet, no receptors 
for the protein have been identiﬁ  ed (Hannappel et al 1982; 
Hannappel and Leibold 1985; Hannappel and van Kampen 
1987). A recent study suggests that internalization of exog-
enous Tβ4 is essential for its subsequent cellular functions 
(Ho et al 2007).
Previous work identiﬁ  ed Tβ4 as an induced gene in 
endothelial cells undergoing differentiation in vitro (Grant 
et al 1995). Tβ4 is active for endothelial cell and kerati-
nocyte migration in vitro and for angiogenesis in vivo 
(Malinda et al 1997; Malinda et al 1999). Tβ4 levels are 
highest in platelets and polymorphonuclear neutrophilic 
leukocytes (PMN), which are among the ﬁ  rst formed 
elements and cells, respectively, to enter a wound and 
release their factors, some of which recruit additional 
cells to the wound site (Cassimeris et al 1992). Although 
the mechanism(s) of action of exogenous Tβ4 on wound 
repair remains unclear, the high levels of Tβ4 present in 
human wound ﬂ  uid (13 μg/ml) suggest its importance in 
wound healing (Frohm et al 1996). Tβ4 promotes cardio-
myocyte migration, survival, and repair after experimental 
myocardial infarction, suggesting its potential as a new 
therapeutic target in the setting of acute myocardial dam-
age (Bock-Marquette et al 2004). It is interesting to note 
Table 2 Thymosin β4: Some potential clinical ocular applications
• Inﬂ  ammatory
  - Dry Eyes, Uveitis, Corneal Melts
• Infectious Keratitis (Bacterial, Viral and Fungal)
• Metabolic
  - Diabetic Eye Disease (Keratopathy)
• Trauma (chemical injury)
• Post Operative: cataract surgery, LASIK (Epi-LASIK, LASEK), PRK
• Other: Corneal transplants (PKP), Neurotrophic ulcers, Persistent
  epithelial defects, Recurrent erosions, Corneal abrasions
Table 1 Properties of thymosin beta 4 in the eye
• Stimulates corneal and conjunctival epithelial cell migration in vitro
• Modulates production of metalloproteinases (MMP-1, -2, and -9)
• Accelerates corneal re-epithelialization in vivo after alkali injury and
 scrape  wounding
• Inhibits corneal neutrophil inﬁ  ltration after alkali injury in vivo
• Modulates and down-regulates a number of key inﬂ  ammatory cytokines
 (IL-1β, TNF-α) and chemokines (MIP-1α and β, MIP-2, MCP-1) 
  in the cornea
• Inhibits TNF-α-stimulated NFκB activation and nuclear translocation in 
  corneal epithelial cells
• Increases TGF-β1 and laminin-5 expression in corneal epithelial cells
• Inhibits corneal epithelial cell apoptosisClinical Ophthalmology 2007:1(3) 203
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that Tβ4 does not have any effect on cell proliferation 
(Leeanansaksiri et al 2004; Huang et al 2006; Sosne 
et al 2006).
In addition to its effects on wound healing, the anti-
inflammatory properties of Tβ4 are beginning to be 
elucidated. Young et al (1999) reported that Tβ4 inhibited 
PMN chemotaxis to the bacterial chemoattractant, N-for-
myl-methionyl-leucyl-phenylalanine (fMLP). Whether 
Tβ4 exerts its effects on PMN directly or indirectly is an 
intriguing question. Other studies showed that the activa-
tion-responsive expression of the lymph-speciﬁ  c form of 
Tβ4 may be one mechanism by which dendritic epidermal 
T cells, and possibly other intraepithelial lymphocytes, 
down-regulate local inﬂ  ammation (Girardi et al 2003). 
In a separate study, Tβ4 lowered circulating levels of 
inﬂ  ammatory cytokines and intermediates following LPS 
administration in vivo (Badamchian et al 2003). Addition-
ally, Tβ4 levels rapidly disappeared in the blood following 
LPS administration or during septic shock, suggesting that 
it may be involved in early events leading to activation 
of the inﬂ  ammatory cascade and ultimately the clinical 
sequelae of sepsis.
Tβ4 stimulates corneal epithelial cell 
migration and wound healing
Two major epithelial cell responses to wounding are cell 
migration to cover the wound bed, and cell proliferation 
to re-epithelialize the wound. We and others have shown 
that while not affecting cell proliferation, Tβ4 signiﬁ  cantly 
enhances the migration of endothelial cells, keratinocytes, 
tumor cells, and corneal epithelial cells (Sosne et al 2001, 
2007; Moon et al 2006; Philp et al 2006). It has been 
proposed that Tβ4 may promote migration via its upregu-
lation of zyxin expression, a protein that regulates the 
actin cytoskeleton (Moon et al 2006). Tβ4 promoted full 
thickness dermal wound repair in normal, steroid-treated 
and diabetic animal models (Malinda et al 1999; Philp et al 
2003). These ﬁ  ndings suggest that Tβ4 may be useful in 
promoting corneal wound healing in healthy individuals 
as well as in people with healing-impaired pathologies 
like diabetes.
Because diabetic retinopathy (DR) corneas have delayed 
wound healing (Kabosova et al 2003), we investigated the 
expression of Tβ4, a potent epithelial cell migration stimula-
tor, in DR corneas. Human DR corneas were analyzed by 
gene microarray and quantitative RT-PCR and were found 
to express signiﬁ  cantly less Tβ4 compared to normal cor-
neas (Saghizadeh et al 2006). We hypothesize that reduced 
expression of Tβ4 may contribute to delayed wound healing 
in DR corneas. These ﬁ  ndings may have important clinical 
relevance in the treatment of complications stemming from 
diabetic keratopathy.
In addition to systemic diseases that manifest in the 
cornea such as diabetic keratopathy, other commonly seen 
corneal wounds can range from simple epithelial scrape 
wounds, recurrent erosions, persistent epitheliopathies 
post-refractive surgery, to severe inflammatory reac-
tions such as seen in alkali injury. Tβ4 accelerated the 
re-epithelialization of corneal wounds in both heptanol 
debridement and alkali-burn animal models (Sosne et al 





















Figure 1 Tβ4 promotes corneal wound healing. By modulating the corneal inﬂ  ammatory response and promoting re-epithelialization in response to injury, Tβ4 may be a 
new a therapeutic option for ophthalmologists treating corneal inﬂ  ammatory and wound healing disorders.Clinical Ophthalmology 2007:1(3) 204
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PMN inﬁ  ltration and inﬂ  ammatory response characterized 
by over-expression of pro-inﬂ  ammatory cytokines/che-
mokines and matrix-metalloproteinases (MMPs), much 
more extreme than that seen in the setting of scrape injury 
(Wagoner, 1997; Kenyon et al 1979; Foster et al 1982). 
The mouse alkali burn model mimics many aspects of 
the injury seen in humans by clinical slit-lamp and histo-
pathological criteria. Slit-lamp observations of mouse eyes 
with alkali injury showed that 70% had readily apparent 
hyphema and total corneal opaciﬁ  cation. In contrast 20% 
of alkali-injured eyes treated with Tβ4 exhibited the same 
characteristics. The overall anatomical integrity of the 
anterior segment in the Tβ4-treated eyes was markedly 
more normal in appearance, providing evidence that Tβ4 
treatment improves corneal healing and clarity following 
alkali injury (Sosne et al 2005).
Corneal epithelial wounds cannot heal properly without 
the re-establishment of cell attachment to the underlying 
connective tissue ie, basement membrane. Hemidesmo-
somes, specialized adhesion junctions present along the 
basal cell membrane of the basal cells of stratiﬁ  ed squamous 
epithelia, are involved in the adherence of the basal cells 
to the basement membrane (Susi et al 1967; Jones et al 
1994). Heptanol or alkali-burned corneal epithelial cells 
treated with Tβ4 showed more hemidesmosomal adhesions 
to the basement membrane, and less widening of the space 
between epithelium and basement membrane. Laminin-5 is 
a major glycoprotein of the basement membrane underly-
ing corneal epithelial cells. It plays a central role in both 
epithelial cell migration and in adhesion, and is associated 
with hemidesmosomes (Larjava et al 1993). In cultured 
corneal epithelial cells and in mouse cornea wounded by 
scraping, topical Tβ4 treatment resulted in increased laminin-
5 expression (Sosne et al 2002). This property of Tβ4 has 
important clinical implications, since it could be utilized 
in the treatment of recurrent erosions or other situations 
in which corneal epithelial cell adhesion to the basement 
membrane is impaired.
As an essential step in the cascade of cellular events 
culminating in wound healing, epithelial cells participate in 
extracellular matrix synthesis and remodeling (Lu et al 2001; 
Santoro and Gaudino 2005). Human MMPs are a family 
of more than 20 zinc-dependent endopeptidases that upon 
activation degrade both matrix and non-matrix proteins as 
part of key rate-limiting steps in tissue repair and remodel-
ing (Nagase et al 2006). Tβ4 treatment modulates MMP 
expression in several epithelial models (Sosne et al 2005; 
2007; Philp et al 2006). The majority of MMPs is secreted 
from the cell as non-catalytic zymogens (pro-MMPs) and 
is activated via removal of the inhibitory propeptides by 
proteinases such as thrombin, plasmin, trypsin, and other 
activated MMPs. Studies suggest that part of the wound heal-
ing activity of Tβ4 may be related to its ability to transiently 
increase MMP activity (MMP-1, -2, and -9) via its central 
actin-binding domain (Philp et al 2006).
Using an in vitro model of corneal epithelial cell scrape 
wound healing we showed that blocking MMP activity with 
speciﬁ  c or broad-spectrum inhibitors decreased Tβ4-mediated 
epithelial cell migration. This suggests that MMP catalytic 
activity is necessary for Tβ4 promotion of epithelial cell 
migration (Sosne et al 2007). Alterations in MMP expres-
sion are linked to improper corneal wound healing and 
the formation of persistent epithelial defects and chronic 
corneal ulcers (Fini et al 1996). Tβ4 differentially regulates 
the expression of MMPs in many tissues, and also regulates 
the MMP/TIMP balance in the cornea. Thus, it is plausible 
to hypothesize that Tβ4 may promote corneal repair and 
matrix remodeling following wounding by modulating MMP 
expression and activity.
Tβ4 modulates corneal 
inﬂ  ammation
Many studies have contributed information regarding the 
roles of cytokine and chemokine expression and activity in 
the post-wound corneal inﬂ  ammatory response in a wide 
array of clinical pathologies (Gillitzer and Goebeler 2001; 
Wilson et al 2003; Agrawal and Tsai 2003; Stramer et al 
2004). For example, in chemically injured corneal epithe-
lial cells, the levels of pro-inﬂ  ammatory cytokines and 
chemokines are upregulated (Planck et al 1997; Sotozono 
et al 1997; Sosne et al 2002), and dry eye stimulates the 
expression of tumour necrosis factor-alpha (TNF-α) in mice 
(Luo et al 2004). Corneal epithelial monolayers infected 
with Pseudomonas aeruginosa demonstrated increased 
expression and secretion of IL-6, IL-8, and TNF-α (Zhang 
et al 2005). IL-6 has been associated with enhanced corneal 
epithelial cell migration (Wang et al 1994; Nakamura and 
Nishida 1999).
In the ﬁ  rst ocular studies to provide evidence that Tβ4-
treatment accelerates in vivo wound healing and modulates 
corneal cytokine production, we showed in the rat corneal 
epithelial debridement model that mRNA transcripts for 
IL-1β and IL-6 were increased in Tβ4-treated corneas after 
injury. Additionally, topical Tβ4 treatment after alkali injury 
down-regulated the expression of the potent PMN chemoat-
tractants, MIP-2 and KC, in the murine cornea. We suggested Clinical Ophthalmology 2007:1(3) 205
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that these cytokines may be involved in corneal inﬂ  ammation 
and wound healing, and that the decreased corneal chemokine 
expression may be responsible for the observed decreased 
PMN inﬁ  ltration.
TNF-alpha is a potent pro-inﬂ  ammatory mediator that 
inﬂ  uences wound healing and apoptotic cell death (Zhang 
et al 2004). TNF-α stimulation activates transcription fac-
tors including nuclear factor kappa B (NFκB) (Baud and 
Karin 2001; Hanada and Yoshimura 2002; Ritchie et al 
2004). NFκB dimers are maintained in an inactivated state 
in the cytoplasm by a family of inhibitory proteins, the IκBs. 
IκB can be phosphorylated following cellular stimulation, 
resulting in its degradation and release from the NFκB 
dimer. Activatied NFκB translocates to the nucleus where 
it binds to κB enhancer elements of a wide panel of target 
genes (Karin and Ben-Neriah 2000). Because of its ability 
to regulate the expression of inﬂ  ammatory genes, NFκB is 
believed to play a major role in the inﬂ  ammatory process 
(Hayden and Ghosh 2004).
In cultured human corneal epithelial cells stimulated 
with TNF-α, Tβ4 treatment signiﬁ  cantly decreased nuclear 
NFκB protein levels, NFκB activity, and p65 subunit 
phosphorylation. The nuclear translocation of NFκB was 
also inhibited. Although there are many inﬂ  ammatory sig-
naling pathways, we hypothesize that Tβ4 mediates NFκB 
inﬂ  ammatory signaling pathways in the cornea based on 
our ﬁ  ndings. These observations have important clinical 
implications for the potential role of Tβ4 as a corneal anti-
inﬂ  ammatory agent.
Tβ4 inhibits corneal epithelial 
cell apoptosis
Evidence that Tβ4 functions as an anti-apoptotic agent is 
mounting. HeLa cells that overexpressed Tβ4 showed a 
higher growth rate and a lower percentage of basal apoptosis 
compared to control HeLa cells. In addition, the overex-
pressing cells were more resistant to paclitaxel-induced 
cell death (Oh et al 2006). The death of human corneal 
epithelial cells (HCET) induced by FasL or by hydrogen 
peroxide was signiﬁ  cantly inhibited by Tβ4 treatment. In 
this study it was observed that the internalization of exog-
enous Tβ4 was essential for its anti-apoptotic activity in 
human corneal epithelial cells (Ho et al 2007). Resistance 
to FasL-induced apoptosis was also achieved in SW480 
colon carcinoma cells that overexpressed Tβ4 (Hsiao et al 
2006). Using an in vitro culture model, we demonstrated 
that Tβ4 suppressed ethanol-induced corneal epithelial cell 
apoptosis via the inhibition of caspases and suppression 
of bcl-2 release from mitochondria (Sosne et al 2004). 
In cultured corneal and conjunctival epithelium, Tβ4 did 
not protect cells from benzalkonium chloride-induced 
inhibition of proliferation, but apoptosis was signiﬁ  cantly 
inhibited (Sosne et al 2006).
Regarding the mechanism by which Tβ4 exerts its 
anti-apoptotic activity, it has been suggested that the 
reduction of early cell death initiation signals, such as the 
phosphorylation of c-Jun, may prevent apoptosis of neurons 
(Choi et al 2006). Additionally, it has been demonstrated 
that Tβ4 promotes survival of cardiomyocytes through the 
formation of a functional complex with PINCH and integrin-
linked kinase, resulting in activation of the survival kinase 
Akt (Bock-Marquette et al 2004).
Future directions
The mounting evidence suggesting the use of Tβ4 as a 
novel corneal wound healing and anti-inﬂ  ammatory agent 
presents an exciting new potential therapy for practicing 
ophthalmologists. The plethora of clinical entities related to 
retarded corneal wound healing present signiﬁ  cant challenges 
for the practicing ophthalmologist. Tβ4, a ubiquitous, natu-
rally occurring molecule, has been demonstrated to promote 
corneal re-epithelialization, reduce inﬂ  ammation and inhibit 
apoptosis. From routine corneal injuries such as abrasions 
and recurrent erosions to more severe inﬂ  ammatory-medi-
ated pathologies, ophthalmologists need an agent that can 
quickly promote corneal healing and properly modulate the 
inﬂ  ammatory response.
More basic science studies focused on the mecha-
nisms of action of Tβ4 are needed to help guide future 
clinical applications. For example, it is interesting to 
speculate whether the anti-apoptotic properties of Tβ4 
could help to preserve tissue after acute injury or for 
corneal transplantation. Additionally, Tβ4 may be useful 
as an adjuvant therapy to BAK-containing eye drops to 
prevent the adverse ocular surface side effects seen with 
many anti-glaucoma medications. Regarding the anti-
inflammatory properties of Tβ4, a wide array of clinical 
entities such as inflammatory keratopathies, corneal graft 
rejection, infections, uveitis, and dry eye syndromes may 
be just a few examples of potential therapeutic treatments. 
In addition to the basic science studies, we believe that 
the published animal studies showing Tβ4’s efficacy in a 
variety of models of injury provide a solid basis for testing 
the efficacy and safety of Tβ4 in well controlled clinical 
trials and this is presently being planned (http://www.
regenerx.com).Clinical Ophthalmology 2007:1(3) 206
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